JP2018530624A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018530624A5 JP2018530624A5 JP2018539255A JP2018539255A JP2018530624A5 JP 2018530624 A5 JP2018530624 A5 JP 2018530624A5 JP 2018539255 A JP2018539255 A JP 2018539255A JP 2018539255 A JP2018539255 A JP 2018539255A JP 2018530624 A5 JP2018530624 A5 JP 2018530624A5
- Authority
- JP
- Japan
- Prior art keywords
- infectious agent
- combination
- item
- tumor
- immunomodulator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012678 infectious agent Substances 0.000 claims description 35
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 239000002955 immunomodulating agent Substances 0.000 claims description 20
- 229940121354 immunomodulator Drugs 0.000 claims description 19
- 230000002584 immunomodulator Effects 0.000 claims description 18
- 241000700605 Viruses Species 0.000 claims description 6
- 208000019420 lymphoid neoplasm Diseases 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- -1 CCL4 Proteins 0.000 claims description 4
- 102100030090 Probable ATP-dependent RNA helicase DHX58 Human genes 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 4
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 3
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 3
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims description 3
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 3
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 3
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 3
- 229960001438 immunostimulant agent Drugs 0.000 claims description 3
- 239000003022 immunostimulating agent Substances 0.000 claims description 3
- 230000003308 immunostimulating effect Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 102100036842 C-C motif chemokine 19 Human genes 0.000 claims description 2
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims description 2
- 102100038078 CD276 antigen Human genes 0.000 claims description 2
- 101710185679 CD276 antigen Proteins 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims description 2
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 2
- 101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 claims description 2
- 101000864662 Homo sapiens Probable ATP-dependent RNA helicase DHX58 Proteins 0.000 claims description 2
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 claims description 2
- 101000763537 Homo sapiens Toll-like receptor 10 Proteins 0.000 claims description 2
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims description 2
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 2
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims description 2
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 claims description 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 2
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 2
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102000013462 Interleukin-12 Human genes 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- 102000002698 KIR Receptors Human genes 0.000 claims description 2
- 108010043610 KIR Receptors Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 2
- 102000002689 Toll-like receptor Human genes 0.000 claims description 2
- 108020000411 Toll-like receptor Proteins 0.000 claims description 2
- 102100027010 Toll-like receptor 1 Human genes 0.000 claims description 2
- 102100027009 Toll-like receptor 10 Human genes 0.000 claims description 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims description 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 2
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims description 2
- 102100039387 Toll-like receptor 6 Human genes 0.000 claims description 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 2
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims description 2
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 2
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 2
- 229940126546 immune checkpoint molecule Drugs 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 41
- 244000309459 oncolytic virus Species 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102100035473 2'-5'-oligoadenylate synthase-like protein Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102100031150 Growth arrest and DNA damage-inducible protein GADD45 alpha Human genes 0.000 description 1
- 102100035688 Guanylate-binding protein 1 Human genes 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 101000597360 Homo sapiens 2'-5'-oligoadenylate synthase-like protein Proteins 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 description 1
- 101001001336 Homo sapiens Guanylate-binding protein 1 Proteins 0.000 description 1
- 101000604998 Homo sapiens Lysosome-associated membrane glycoprotein 3 Proteins 0.000 description 1
- 101001014059 Homo sapiens Metallothionein-2 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 description 1
- 101000843562 Homo sapiens Transcription factor HES-4 Proteins 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 102100038213 Lysosome-associated membrane glycoprotein 3 Human genes 0.000 description 1
- 102100031347 Metallothionein-2 Human genes 0.000 description 1
- 108091033773 MiR-155 Proteins 0.000 description 1
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 101710138750 Transcription factor E2F1 Proteins 0.000 description 1
- 102100030774 Transcription factor HES-4 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- ONVRFFJRASWLTG-UHFFFAOYSA-N [(1-amino-2-naphthalen-1-ylethylidene)amino] morpholine-4-carboxylate Chemical compound C=1C=CC2=CC=CC=C2C=1CC(N)=NOC(=O)N1CCOCC1 ONVRFFJRASWLTG-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 102000046157 human CSF2 Human genes 0.000 description 1
- 102000050313 human E2F1 Human genes 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021067054A JP2021105052A (ja) | 2015-10-19 | 2021-04-12 | 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562243512P | 2015-10-19 | 2015-10-19 | |
| US62/243,512 | 2015-10-19 | ||
| PCT/US2016/057526 WO2017070110A1 (en) | 2015-10-19 | 2016-10-18 | Methods of treating solid or lymphatic tumors by combination therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021067054A Division JP2021105052A (ja) | 2015-10-19 | 2021-04-12 | 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018530624A JP2018530624A (ja) | 2018-10-18 |
| JP2018530624A5 true JP2018530624A5 (enExample) | 2019-12-05 |
| JP6954648B2 JP6954648B2 (ja) | 2021-10-27 |
Family
ID=58557947
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539255A Active JP6954648B2 (ja) | 2015-10-19 | 2016-10-18 | 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法 |
| JP2021067054A Withdrawn JP2021105052A (ja) | 2015-10-19 | 2021-04-12 | 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021067054A Withdrawn JP2021105052A (ja) | 2015-10-19 | 2021-04-12 | 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20180318365A1 (enExample) |
| EP (1) | EP3365062B1 (enExample) |
| JP (2) | JP6954648B2 (enExample) |
| CN (1) | CN108135934B (enExample) |
| ES (1) | ES2994611T3 (enExample) |
| TW (1) | TW201722477A (enExample) |
| WO (1) | WO2017070110A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| KR102089121B1 (ko) | 2013-03-14 | 2020-03-13 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양살상형 아데노바이러스 조성물 |
| FI3077041T3 (fi) | 2013-12-05 | 2024-10-16 | Rfemb Holdings Llc | Syövän immunoterapia radiotaajuisella sähköisellä solukalvon hajotuksella (rf-emb) |
| EP3092049A1 (en) | 2014-01-08 | 2016-11-16 | Flodesign Sonics Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| US11141216B2 (en) | 2015-01-30 | 2021-10-12 | Immunsys, Inc. | Radio-frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| GB201522311D0 (en) * | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
| CA3011460A1 (en) * | 2016-01-15 | 2017-07-20 | Rfemb Holdings, Llc | Immunologic treatment of cancer |
| AU2017212713B2 (en) | 2016-01-27 | 2023-01-19 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| CA3013637A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| KR20180112024A (ko) | 2016-02-23 | 2018-10-11 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현 |
| EP3426271B1 (en) * | 2016-03-10 | 2025-08-27 | CG Oncology, Inc. | Methods of treating solid tumors by combination therapy |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| NZ749355A (en) | 2016-05-27 | 2023-04-28 | Agenus Inc | Anti-tim-3 antibodies and methods of use thereof |
| RU2021127872A (ru) | 2016-06-30 | 2021-11-09 | Онкорус, Инк. | Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| TWI843168B (zh) | 2016-10-11 | 2024-05-21 | 美商艾吉納斯公司 | 抗ｌａｇ－３抗體及其使用方法 |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| AU2018251987B2 (en) * | 2017-04-14 | 2024-11-28 | Cg Oncology, Inc. | Methods of treating bladder cancer |
| WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
| RU2771110C2 (ru) | 2017-07-26 | 2022-04-26 | Онкорус, Инк. | Онколитические вирусные векторы и их применение |
| EP3681998A1 (en) | 2017-09-11 | 2020-07-22 | IMBA-Institut für Molekulare Biotechnologie GmbH | Tumor organoid model |
| JP2021507561A (ja) | 2017-12-14 | 2021-02-22 | フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． | 音響トランスデューサドライバ及びコントローラ |
| EP3731850A4 (en) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
| JP7550449B2 (ja) * | 2018-04-02 | 2024-09-13 | デューク ユニバーシティ | ネオアジュバントがん治療 |
| AU2019251356B2 (en) | 2018-04-09 | 2025-06-12 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions with enhanced replication properties |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CN113891747A (zh) * | 2019-05-15 | 2022-01-04 | 郑州威瑞生物技术有限公司 | 诱导免疫细胞活性的组合物及使用该组合物治疗疾病的方法 |
| CN110684743A (zh) * | 2019-07-16 | 2020-01-14 | 伍泽堂 | 特异性杀伤肿瘤细胞的病毒和肿瘤治疗药物 |
| US20220356529A1 (en) * | 2019-07-16 | 2022-11-10 | Université Cote D'azur | Method of assessing the sensitivity or resistance of a subject to an oncolytic virus, recombinant virus, preparation and uses thereof |
| EP4054612A4 (en) * | 2019-11-07 | 2023-08-02 | Baylor College of Medicine | ONCOLYTIC VIROTHERAPY AND IMMUNOTHERAPY |
| PH12022551208A1 (en) | 2019-11-18 | 2023-04-24 | Janssen Biotech Inc | Vaccines based on mutant calr and jak2 and their uses |
| US20230002499A1 (en) * | 2019-11-21 | 2023-01-05 | Beigene (Beijing) Co., Ltd. | Methods of cancer treatment with anti-ox40 antibody in combination with chemotherapeutic agents |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4215214A4 (en) * | 2020-09-16 | 2024-07-03 | Osaka University | THERAPEUTIC AGENT AGAINST CANCER, IMMUNOSTIMULANT AND SCREENING METHOD FOR ANTI-CANCER SUBSTANCE |
| US20220170042A1 (en) * | 2020-11-27 | 2022-06-02 | Wyvern Pharmaceuticals Inc. | Compositions and methods for regulating production of a precursor protein |
| JP2023553010A (ja) | 2020-12-03 | 2023-12-20 | バテル・メモリアル・インスティテュート | 非ウイルス性送達のためのポリマーナノ粒子およびｄｎａナノ構造組成物ならびに方法 |
| CN112516319A (zh) * | 2020-12-08 | 2021-03-19 | 华中农业大学 | 用于治疗乳腺癌的组合药剂 |
| US20240066108A1 (en) * | 2021-01-08 | 2024-02-29 | The Regents Of The University Of California | Ovarian cancer vaccine |
| JP2024516108A (ja) | 2021-04-07 | 2024-04-12 | バテル・メモリアル・インスティテュート | 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術 |
| CN115989321A (zh) * | 2021-08-17 | 2023-04-18 | 上海行深生物科技有限公司 | 病毒制剂、用于配制病毒制剂的溶液及其用途 |
| CN114983932A (zh) * | 2022-06-06 | 2022-09-02 | 上海市第一人民医院 | 一种用于多形性胶质母细胞瘤的诊疗纳米复合物及其制备方法和应用 |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| WO2025122954A1 (en) | 2023-12-08 | 2025-06-12 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07291996A (ja) | 1994-03-01 | 1995-11-07 | Yuu Honshiyo | ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物 |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US20080213778A1 (en) | 1998-12-30 | 2008-09-04 | Millennium Pharmaceuticals, Inc. | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses |
| US7041474B2 (en) | 1998-12-30 | 2006-05-09 | Millennium Pharmaceuticals, Inc. | Nucleic acid encoding human tango 509 |
| PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| ES2282133T3 (es) | 1999-08-24 | 2007-10-16 | Medarex, Inc. | Anticuerpos frente a la ctla-4 humano y sus usos. |
| CA3016482A1 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
| US6687360B2 (en) | 1999-12-30 | 2004-02-03 | At&T Corp. | Personal IP follow-me service |
| US7048920B2 (en) * | 2000-03-24 | 2006-05-23 | Cell Genesys, Inc. | Recombinant oncolytic adenovirus for human melanoma |
| NZ522844A (en) | 2000-06-28 | 2005-02-25 | Brigham & Womens Hospital | PD-L2 molecules: novel PD-1 ligands and methods to identify compounds to modulate T cell activation |
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| WO2003086459A1 (en) | 2002-04-12 | 2003-10-23 | Medarex, Inc. | Methods of treatement using ctla-4 antibodies |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| US7459154B2 (en) * | 2002-12-26 | 2008-12-02 | Cell Genesys, Inc. | Methods and reagents for the enhancement of virus transduction in the bladder epithelium |
| US20050186178A1 (en) | 2003-08-28 | 2005-08-25 | Ennist David L. | Oncolytic adenoviral vectors encoding GM-CSF |
| JP5303146B2 (ja) | 2004-10-06 | 2013-10-02 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | Ｂ７−ｈ１ならびに癌の診断、予後診断および処置の方法 |
| CN1799625B (zh) * | 2004-12-14 | 2012-09-26 | 诺华疫苗和诊断公司 | 制备用于药用的白介素 |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US8557257B2 (en) * | 2006-03-24 | 2013-10-15 | Oncovac Inc. | Mycobacterial immunotherapy for cancer treatment |
| JP6092497B2 (ja) | 2006-03-30 | 2017-03-08 | ユニバーシティー オブ カリフォルニア | 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物 |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| WO2010027423A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| HUE030807T2 (en) | 2008-09-26 | 2017-05-29 | Dana Farber Cancer Inst Inc | Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications |
| TWI605828B (zh) | 2008-12-09 | 2017-11-21 | 建南德克公司 | 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途 |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| BR112013006669A2 (pt) * | 2010-09-24 | 2019-09-24 | Oncos Therapeutics Oy | vetores adenovirais oncolíticos e métodos e usos relacionados aos mesmos |
| DK2646552T3 (en) | 2010-12-02 | 2017-10-23 | Pieris Pharmaceuticals Gmbh | MUTEINES OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR CTLA-4 |
| EP3403672A1 (en) | 2011-04-20 | 2018-11-21 | Medlmmune, LLC | Antibodies and other molecules that bind b7-h1 and pd-1 |
| US9056133B2 (en) * | 2011-05-25 | 2015-06-16 | Cti-S.A. | Pharmaceutical kit and method for treating cancer |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| KR20150038066A (ko) * | 2012-07-30 | 2015-04-08 | 알렉스 와 힌 영 | 종양 세포, 암세포파괴 바이러스 벡터 및 면역 체크포인트 조절인자를 갖는 암 백신 시스템 |
| JP2016540505A (ja) * | 2013-11-22 | 2016-12-28 | ディーエヌエートリックス インコーポレイテッド | アデノウイルス発現免疫細胞刺激受容体アゴニスト |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| EP3426271B1 (en) * | 2016-03-10 | 2025-08-27 | CG Oncology, Inc. | Methods of treating solid tumors by combination therapy |
-
2016
- 2016-10-18 JP JP2018539255A patent/JP6954648B2/ja active Active
- 2016-10-18 ES ES16858069T patent/ES2994611T3/es active Active
- 2016-10-18 WO PCT/US2016/057526 patent/WO2017070110A1/en not_active Ceased
- 2016-10-18 EP EP16858069.4A patent/EP3365062B1/en active Active
- 2016-10-18 US US15/769,057 patent/US20180318365A1/en not_active Abandoned
- 2016-10-18 CN CN201680061031.5A patent/CN108135934B/zh active Active
- 2016-10-19 TW TW105133787A patent/TW201722477A/zh unknown
-
2021
- 2021-04-12 JP JP2021067054A patent/JP2021105052A/ja not_active Withdrawn
- 2021-06-04 US US17/339,885 patent/US20220125864A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018530624A5 (enExample) | ||
| JP2019507761A5 (enExample) | ||
| Wang et al. | mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications | |
| Gu et al. | mRNA vaccines in the prevention and treatment of diseases | |
| US12410392B2 (en) | Delivery of biomolecules to immune cells | |
| Pardi et al. | Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes | |
| Goutagny et al. | Targeting pattern recognition receptors in cancer immunotherapy | |
| Dewitte et al. | Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment | |
| JP2022519557A (ja) | 脂質ナノ粒子の調製方法 | |
| US11596685B2 (en) | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids | |
| JP7570080B2 (ja) | 樹状細胞免疫療法 | |
| Zamarin et al. | Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer | |
| FI3294325T3 (fi) | Car-muokattujen t-solujen vaikutuksen parantaminen nukleeinihapporokotuksella | |
| US11065331B2 (en) | Immune adjuvant for cancer | |
| FI3728313T3 (fi) | Syövän yhdistelmähoito IAP-antagonistilla ja anti-PD-1-molekyylillä | |
| JP2020516590A5 (enExample) | ||
| CN119563028A (zh) | 具有分泌抗原和免疫调节物的合成自扩增mRNA分子 | |
| Abraham et al. | Gene-modified dendritic cell vaccines for cancer | |
| U'ren et al. | Vaccination with liposome–DNA complexes elicits enhanced antitumor immunity | |
| Alyamkina et al. | Effects of human exogenous DNA on production of perforin-containing CD8+ cytotoxic lymphocytes in laboratory setting and clinical practice | |
| Warricker et al. | The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma | |
| Brown | Engaging pattern recognition receptors in solid tumors to generate systemic antitumor immunity | |
| JPWO2020036635A5 (enExample) | ||
| JP2025049296A (ja) | 高度にコンパクトな多入力論理ゲートをコードする核酸ベクターを使用して疾患を処置する方法 | |
| Tscharke et al. | From mice to humans–murine intelligence for human CD8+ T cell vaccine design |